David Serur, MD
Nephrology · Hackensack, NJNPI 1023070851
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,352 of the $10,580 with a category attached, or 78.9%. Sanofi-aventis U.S. LLC accounts for 78.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $8,259 and has fallen 99.6% since, to $32 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $587.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$8K
- Vifor Pharma, Inc.$2K
- Mallinckrodt Enterprises LLC$197
- Dilon Technologies, Inc.$173
- Veloxis Pharmaceuticals, Inc.$168
- AstraZeneca$129
- plus $154 from 3 others
What the payments were for
- Consulting fees$8,35279%
- Travel & lodging$1,02510%
- Food & beverage$1,12811%
- Education$751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 8 | $8,259 |
| Vifor Pharma, Inc. | 1 | $1,500 |
| Mallinckrodt Enterprises LLC | 2 | $197 |
| Dilon Technologies, Inc. | 1 | $173 |
| Veloxis Pharmaceuticals, Inc. | 2 | $168 |
| AstraZeneca | 1 | $129 |
| Sanofi | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$8,295
- Veltassa$1,500
- HemoBlast Bellows$173
- Envarsus$149
- LOKELMA$129
- ACTHAR$122
How this compares
$10,580 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $70,451 |
| Mycophenolic AcidMycophenolate Sodium | 142 | $32,333 |
| Valganciclovir Hcl | 95 | $31,419 |
| LokelmaSodium Zirconium Cyclosilicate | 47 | $28,447 |
| Tacrolimus | 121 | $20,029 |
| Cinacalcet Hcl | 89 | $15,933 |
| Leflunomide | 65 | $12,975 |
| Nifedipine ErNifedipine | 508 | $8,678 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $7,540 |
| XareltoRivaroxaban | 12 | $7,056 |
| MyrbetriqMirabegron | 12 | $6,694 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $6,610 |
| Methenamine Hippurate | 62 | $6,050 |
| Novolog FlexpenInsulin Aspart | 40 | $5,555 |
| Labetalol Hcl | 166 | $4,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $129 | $28,44747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Hackensack
- Rosy JosephHackensack$5K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.